Rapport Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Rapport Therapeutics, Inc. (RAPP) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $63.72 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $63.72M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $78.16M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $52.75M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $251.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $63.72M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $78.16M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $52.75M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $251.46M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $55.17M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $57.71M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $56.91M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $39.42M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $110.27M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $74.37M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $70.25M 10-K · filed 2026-03-10 |
| 2023-09-30 | $159.41M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $79.53M 10-Q · filed 2024-08-08 |
| 2022-12-31 | $31.16M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |